Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy

EuroIntervention 2018;13:1923-1930 published online November 2017. DOI: 10.4244/EIJ-D-17-00792

Byoung-Kwon Lee
Byoung-Kwon Lee1, MD; Jung-Sun Kim2, MD; Oh-Hyun Lee1, MD; Pil-Ki Min1, MD; Young-Won Yoon1, MD; Bum-Kee Hong1, MD; Dong-Ho Shin2, MD, MPH; Tae-Soo Kang3, MD; Byung Ok Kim4, MD; Deok-Kyu Cho5, MD; Dong Woon Jeon6, MD; Sung-Ill Woo7, MD; Seonghoon Choi8, MD; Yong Hoon Kim9, MD; Woong-Chol Kang10, MD; Seunghwan Kim2, MD; Byeong-Keuk Kim2, MD; Myeong-Ki Hong2, MD; Yangsoo Jang2, MD; Hyuck Moon Kwon1*
1. Division of Cardiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea; 2. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; 3. Dankook Universit

Aims: There are few randomised studies concerning the optimal duration of dual antiplatelet therapy (DAPT) for patients who receive a second-generation drug-eluting stent (DES). This tria

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

adjunctive pharmacotherapyclinical researchoptical coherence tomography
Stents and scaffolds
Read next article
Comparison of the effects of P2Y12 receptor antagonists on platelet function in patients undergoing primary PCI: a substudy of the HEAT-PPCI trial

Latest news